All In MedTech

Device Trial Radar · NCT03796559

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

A Prospective Open Label Study of the Use of Magseed® Markers and Sentimag® to Localize Axillary Lymph Nodes With Biopsy-proven Metastases in Breast Cancer Patients

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Jun 13, 2019

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Endomagnetics Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jan 8, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

Conditions

  • Breast Cancer
  • Axillary Lymph Nodes

Interventions

  • Magseed MarkerDevice

    Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Retrieval rate of clipped node and Magseed in the excised specimenTime frame: Time of surgery

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Baylor Medicine

    Houston, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.